Citations

Clear

634 citation(s) found for "Hall, A".

Impact of the COVID ‐19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race
Berrian, Jennifer L. , Ezenwajiaku, Nkiruka, Moreno‐Aspitia, Alvaro , Toriola, Adetunji T. , Colditz, Graham A. , Housten, Ashley J. , Hall, Lannis, Fiala, Mark A. , Holton, Sara J, Toriola, Adetunji T , Colditz, Graham A , Housten, Ashley J , Ademuyiwa, Foluso O , Fiala, Mark A , Liu, Ying , Holton, Sara J., Ademuyiwa, Foluso O.

Mayo Clinic

Cancer Medicine | November 21, 2022 | Volume: 12 | Issue: 6 | Pages: 7381-7388

10.1002/cam4.5439 | PMID 36404491 Get It

Abstract Purpose To determine if the COVID‐19 pandemic has further exacerbated racial disparities in late‐stage presentation of breast, colorectal, lung, and prostate cancers. Methods We conducted a registry‐based retrospective study of patients with newly reported diagnoses of breast, colorectal, lung, and prostate cancers between March 2019–June 2019 (pre‐COVID‐19) and March 2020–June 2020 (early‐COVID‐19). We compared the volume of new diagnoses and stage at presentation according to race between both periods. Results During the study period, a total of 3528 patients had newly diagnosed cancer; 3304 of which had known disease stages and were included in the formal analyses. 467 (14.1%) were Blacks, and 2743 were (83%) Whites. 1216 (36.8%) had breast, 415 (12.6%) had colorectal, 827 (25%) had lung, and 846 (25.6%) had prostate cancers, respectively. The pre‐COVID‐19 period included 2120 (64.2%), and the early‐COVID‐19 period included 1184 (35.8%), representing a proportional 44.2% decline in the volume of new cases of breast, colorectal, lung, and prostate cancers, p < 0.0001. Pre‐COVID‐19, 16.8% were diagnosed with metastatic disease, versus 20.4% early‐COVID‐19, representing a proportional increase of 21.4% in the numbers of new cases with metastatic disease, p = 0.01. There was a non‐significant proportional decline of 1.9% in Black patients diagnosed with non‐metastatic breast, colorectal, lung, and prostate cancers early‐COVID‐19 ( p = 0.71) and a non‐significant proportional increase of 7% in Black patients diagnosed with metastatic disease ( p = 0.71). Difference‐in‐difference analyses showed no statistically significant differences in metastatic presentation comparing Black to White patients. Conclusion While we identified substantial reductions in the volume of new cancer diagnoses and increases in metastatic presentations due to the COVID‐19 pandemic, the impact was similar for White and Black patients.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Pemmaraju, Naveen , Kantarjian, Hagop M. , Sweet, Kendra , Senapati, Jayastu , Konopleva, Marina , Frankel, Arthur E. , Gupta, Vikas , Ulrickson, Matthew L. , Gorak, Edward J., Bhatia, Sumeet, Budak-Alpdoǧan, Tülin , Mason, James R. , García‐Romero, María Teresa , López‐Santiago, Norma, Vachhani, Pankit , Lee, Sangmin , Blum, William , Walter, Roland B. , Bixby, Dale L. , Gojo, Ivana , Rampal, Raajit K. , Foran, James M. , Fathi, Amir T. , Hall, Aric C. , Jacoby, Meagan A., Mannis, Gabriel N. , Stein, Anthony S. , Rizzieri, David A. , Olin, Rebecca L. , Perl, Alexander E. , Schiller, Gary J. , Shami, Paul J. , Stone, Richard M. , Wieduwilt, Matthew J. , Vasu, Sumithira , Khoury, Joseph D. , Qazilbash, Muzaffar H. , Cuglievan, Branko , Madanat, Yazan F. , Kharfan‐Dabaja, Mohamed A. , Tallman, Martin S. , Dhakal, Prajwal , Senapati, Jayastu , Konopleva, Marina , Gupta, Vikas , Budak-Alpdogan, Tulin , Garcia-Romero, Maria Teresa , Cesarman-Maus, Gabriela , Vachhani, Pankit , Bhatt, Vijaya Raj , Walter, Roland B , Fathi, Amir T , Hall, Aric Cameron , Mims, Alice S , Rizzieri, David A , Perl, Alexander E , Strickland, Stephen Anthony , Daver, Naval , Guzmán, Mónica L. , Roboz, Gail J , Khoury, Joseph , Aung, Phyu P , Madanat, Yazan , Kharfan-Dabaja, Mohamed A , Pawlowska, Anna , Taylor, Justin , Dhakal, Prajwal , Lane, Andrew A , Kantarjian, Hagop , Wang, Eunice S. , Wilson, Nathaniel R. , Mesa, Ruben A. , Cesarman‐Maus, Gabriela , Bhatt, Vijaya Raj , Duvic, Madeleine , Lima, Marcos de , Lancet, Jeffrey E. , Daver, Naval , Ravandi, Farhad , Roboz, Gail J. , Lane, Andrew A.

Mayo Clinic

Blood | November 18, 2022 | Volume: 141 | Issue: 6 | Pages: 567-578

10.1182/blood.2022017865 | PMID 36399715 Get It

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3Rα) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged ≥2 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC’s inaugural meetings are presented herein.
Association of Physical Activity With Neurofilament Light Chain Trajectories in Autosomal Dominant Frontotemporal Lobar Degeneration Variant Carriers
Casaletto, Kaitlin B. , Kornack, John, VandeBunte, Anna M. , Staffaroni, Adam S., Lee, Shannon, Heuer, Hilary W. , Forsberg, Leah K. , Ramos, Eliana Marisa , Kramer, Joel H. , Yaffe, Kristine , Petrucelli, Leonard , Boxer, Adam L. , Rosen, Howard J. , Apostolova, Liana G. , Barmada, Sami J. , Bordelon, Yvette , Brushaber, Danielle , Coppola, Giovanni, Darby, Ryan, Domoto-Reilly, Kimiko, Faber, Kelley, Fagan, Anne M. , Fields, Julie A. , Geschwind, Daniel H. , Ghoshal, Nupur , Gavrilova, Ralitza, Graff-Radford, Jonathon, Graff‐Radford, Neill R. , Grant, Ian , Grossman, Murray, Hall, Matthew , Huey, Edward D. , Kauer, Daniel, Kornak, John , Lago, Argentina Lario , Lee, Suzee, Ljubenkov, Peter A. , Lucente, Diana E., Mackenzie, Ian R. , Masdeux, Joseph C., McGinnis, Scott, Mendez, Mario F. , Mester, Carly , Onyike, Chiadi U. , Pascual, María Belén, Rademakers, Rosa , Rao, Meghana , Rascovsky, Katya, Rankin, Katherine P. , Ritter, Aaron, Savica, Rodolfo , Syrjanen, Jeremy A. , Staffaroni, Adam M. , Taylor, Jack C. , Weıntraub, Sandra , Damme, Philip Van , Van Damme, Philip , Barmada, Sami , Paolillo, Emily W. , Rojas, Julio C. , Miller, Bruce L. , Boeve, Bradley F. , Gendron, Tania F. , Appleby, Brian S. , Botha, Hugo , Bozoki, Andrea C , Clark, David , Coppola, Giovanni, Dickerson, Bradford Clark , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Foroud, Tatiana , Goldman, Jill , Galasko, Douglas , Huang, Eric J. , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Kantarci, Kejal , Kerwin, Diana , Knopman, David S. , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Pressman, Peter, Ramanan, Vijay K. , Seeley, William W. , Tartaglia, Maria Carmela , VandeVrede, Lawren , Wong, Bonnie

Mayo Clinic

JAMA Neurology | November 14, 2022 | Volume: 80 | Issue: 1 | Pages: 82

10.1001/jamaneurol.2022.4178 | PMID 36374516 Get It

ImportancePhysical activity is associated with cognitive health, even in autosomal dominant forms of dementia. Higher physical activity is associated with slowed cognitive and functional declines over time in adults carrying autosomal dominant variants for frontotemporal lobar degeneration (FTLD), but whether axonal degeneration is a potential neuroprotective target of physical activity in individuals with FTLD is unknown.ObjectiveTo examine the association between physical activity and longitudinal neurofilament light chain (NfL) trajectories in individuals with autosomal dominant forms of FTLD.Design, Setting, and ParticipantsThis cohort study included individuals from the ALLFTD Consortium, which recruited patients from sites in the US and Canada. Symptomatic and asymptomatic adults with pathogenic variants in one of 3 common genes associated with FTLD (GRN, C9orf72, or MAPT) who reported baseline physical activity levels and completed annual blood draws were assessed annually for up to 4 years. Genotype, clinical measures, and blood draws were collected between December 2014 and June 2019; data were analyzed from August 2021 to January 2022. Associations between reported baseline physical activity and longitudinal plasma NfL changes were assessed using generalized linear mixed-effects models adjusting for baseline age, sex, education, functional severity, and motor symptoms.ExposuresBaseline physical activity levels reported via the Physical Activity Scale for the Elderly. To estimate effect sizes, marginal means were calculated at 3 levels of physical activity: 1 SD above the mean represented high physical activity, 0 SD represented average physical activity, and 1 SD below the mean represented low physical activity.Main Outcomes and MeasuresAnnual plasma NfL concentrations were measured with single-molecule array technology.ResultsOf 160 included FTLD variant carriers, 84 (52.5%) were female, and the mean (SD) age was 50.7 (14.7) years. A total of 51 (31.8%) were symptomatic, and 77 carried the C9orf72 variant; 39, GRN variant; and 44, MAPT variant. Higher baseline physical activity was associated with slower NfL trajectories over time. On average, NfL increased 45.8% (95% CI, 22.5 to 73.7) over 4 years in variant carriers. Variant carriers with high physical activity demonstrated 14.0% (95% CI, −22.7 to −4.3) slower NfL increases compared with those with average physical activity and 30% (95% CI, −52.2 to −8.8) slower NfL increases compared with those with low physical activity. Within genotype, C9orf72 and MAPT carriers with high physical activity evidenced 18% to 21% (95% CI, −43.4 to −7.2) attenuation in NfL, while the association between physical activity and NfL trajectory was not statistically significant in GRN carriers. Activities associated with higher cardiorespiratory and cognitive demands (sports, housework, and yardwork) were most strongly correlated with slower NfL trajectories (vs walking and strength training).Conclusions and RelevanceIn this study, higher reported physical activity was associated with slower progression of an axonal degeneration marker in individuals with autosomal dominant FTLD. Physical activity may serve as a primary prevention target in FTLD.
NIMG-40. RAPID EARLY PROGRESSION (REP) OF GLIOBLASTOMA IS AN INDEPENDENT NEGATIVE PROGNOSTIC FACTOR: RESULTS FROM A SYSTEMATIC REVIEW AND META-ANALYSIS
Villanueva‐Meyer, Javier , Hamer, Philip Witt De, Quiñones‐Hinojosa, Alfredo , Borst, Gerben, Waqar, Mueez , Roncaroli, Federico , Lehrer, Eric J. , Palmer, Joshua D. , Villanueva-Meyer, Javier E. , Braunstein, Steve , Hall, Emma , Aznar, Marianne Camille , D’Urso, Pietro Ivo , Trifiletti, Daniel M. , Wesseling, Pieter

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii172-vii172

10.1093/neuonc/noac209.658 Get It

Abstract INTRODUCTION In patients with newly-diagnosed glioblastoma, rapid early progression (REP) refers to tumour regrowth between surgery and postoperative chemoradiotherapy. This systematic review and meta-analysis appraised published data on REP to better characterise and understand it. METHODS Systematic searches of MEDLINE, EMBASE and the Cochrane database from inception to 21/10/21. Studies describing the incidence of REP – tumour growth between the postoperative MRI scan and pre-radiotherapy MRI scan in newly-diagnosed glioblastoma, were included. The primary outcome was REP incidence. RESULTS From 1590 search results, 9 studies were included with 716 patients. The median age was 56.9 years (IQR 54.0-58.8 years). There was a male predominance with a median male-to-female ratio of 1.4 (IQR 1.1-1.5). The median number of days between MRI scans was 34 days (IQR 18-45 days). The mean incidence rate of REP was 45.9% (range 19.3%-72.0%) and significantly lower in studies employing functional imaging to define REP (p&lt; 0.001). REP/non-REP groups were comparable with respect to age (p=0.99), gender (p=0.33) and time between scans (p=0.81). REP was associated with shortened overall survival (HR 1.78, 95% CI 1.30-2.43, p&lt; 0.001), shortened progression-free survival (HR 1.78, 95% CI 1.30-2.43, p&lt; 0.001), subtotal resection (OR 6.96, 95% CI 4-51-10.73, p&lt; 0.001) and IDH wildtype versus mutant tumours (OR 0.20, 95% CI 0.02-0.38, p=0.03). MGMT promoter methylation was not associated with REP (OR 1.29, 95% CI 0.72-2.28, p=0.39). CONCLUSIONS REP occurs in almost half of patients with newly-diagnosed glioblastoma and has a strongly negative prognostic effect. Future studies should investigate its biology and effective treatment strategies.
Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children
Berbert, Laura , Dallas, Johnathan, Newhams, Margaret M. , Chen, Sabrina , Ardoin, Stacy P. , Basiaga, Matthew L. , Crandall, Hillary , Dhakal, Sanjeev, Sagcal‐Gironella, Anna Carmela P. , Huie, Livie , Jones, Madelyn, Kim, Susan , Lionetti, Geraldina, Mannion, Melissa L. , Muscal, Eyal , Tejtel, S. Kristen Sexson , Villacis-Nunez, D. Sofia , Wu, Eveline Y. , Zambrano, Laura D. , Campbell, Angela P. , Patel, Manish M. , Randolph, Adrienne G. , Investigators, Overcoming COVID-19, Kong, Michele , Tarquinio, Keiko M. , Kücükak, Suden, FitzGerald, Madyson M., Worden, Julie, Levy, Emily R. , Martin, Lora , Malloch, Lacy , Clouser, Katharine N. , Walker, Tracie C. , Hall, Mark W., Staat, Mary Allen , Loftis, Laura L. , Smith, Lincoln , Feldstein, Leora R. , Jackson, Ashley , Levy, Emily R , Randolph, Adrienne G , Kong, Michele , Mannion, Melissa L , Staat, Mary A , Son, Mary Beth F. , Young, Cameron C. , Canny, Susan , Dhanrajani, Anita D. , Hobbs, Charlotte V. , James, Karen, Prahalad, Sampath , Schulert, Grant S , Investigators, Overcoming COVID-19, Cvijanovich, Natalie Z , Zinter, Matt S. , Schwartz, Stephanie P. , Hall, Mark W. , McGuire, John K. , Tenforde, Mark W.

Mayo Clinic

JAMA Network Open | November 11, 2022 | Volume: 5 | Issue: 11 | Pages: e2241622

10.1001/jamanetworkopen.2022.41622 | PMID 36367723 Get It

ImportanceMinimal data are available regarding the postdischarge treatment of multisystem inflammatory syndrome in children (MIS-C).ObjectivesTo evaluate clinical characteristics associated with duration of postdischarge glucocorticoid use and assess postdischarge clinical course, laboratory test result trajectories, and adverse events in a multicenter cohort with MIS-C.Design, Setting, and ParticipantsThis retrospective cohort study included patients with MIS-C hospitalized with severe illness and followed up for 3 months in an ambulatory setting. Patients younger than 21 years who were admitted between May 15, 2020, and May 31, 2021, at 13 US hospitals were included. Inclusion criteria were inpatient treatment comprising intravenous immunoglobulin, diagnosis of cardiovascular dysfunction (vasopressor requirement or left ventricular ejection fraction ≤55%), and availability of complete outpatient data for 3 months.ExposuresGlucocorticoid treatment.Main Outcomes and MeasuresMain outcomes were patient characteristics associated with postdischarge glucocorticoid treatment, laboratory test result trajectories, and adverse events. Multivariable regression was used to evaluate factors associated with postdischarge weight gain (≥2 kg in 3 months) and hyperglycemia during illness.ResultsAmong 186 patients, the median age was 10.4 years (IQR, 6.7-14.2 years); most were male (107 [57.5%]), Black non-Hispanic (60 [32.3%]), and Hispanic or Latino (59 [31.7%]). Most children were critically ill (intensive care unit admission, 163 [87.6%]; vasopressor receipt, 134 [72.0%]) and received inpatient glucocorticoid treatment (178 [95.7%]). Most were discharged with continued glucocorticoid treatment (173 [93.0%]); median discharge dose was 42 mg/d (IQR, 30-60 mg/d) or 1.1 mg/kg/d (IQR, 0.7-1.7 mg/kg/d). Inpatient severity of illness was not associated with duration of postdischarge glucocorticoid treatment. Outpatient treatment duration varied (median, 23 days; IQR, 15-32 days). Time to normalization of C-reactive protein and ferritin levels was similar for glucocorticoid duration of less than 3 weeks vs 3 or more weeks. Readmission occurred in 7 patients (3.8%); none was for cardiovascular dysfunction. Hyperglycemia developed in 14 patients (8.1%). Seventy-five patients (43%) gained 2 kg or more after discharge (median 4.1 kg; IQR, 3.0-6.0 kg). Inpatient high-dose intravenous and oral glucocorticoid therapy was associated with postdischarge weight gain (adjusted odds ratio, 6.91; 95% CI, 1.92-24.91).Conclusions and RelevanceIn this multicenter cohort of patients with MIS-C and cardiovascular dysfunction, postdischarge glucocorticoid treatment was often prolonged, but clinical outcomes were similar in patients prescribed shorter courses. Outpatient weight gain was common. Readmission was infrequent, with none for cardiovascular dysfunction. These findings suggest that strategies are needed to optimize postdischarge glucocorticoid courses for patients with MIS-C.
Characteristics and Outcomes of Sepsis Presenting in Inpatient Pediatric Settings
Schafer, Melissa , Souza, Heidi G. De , Paul, Raina, Riggs, Ruth , Richardson, Troy , Conlon, Patricia M. , Duffy, Susan , Foster, Lauren Z. , Gunderson, Julie , Hall, David E. , Hatcher, Laura, Hess, Lauren M. , Kirkpatrick, Lauren, Kunar, Jillian, Lockwood, Justin , Lowerre, Tracy, McFadden, Vanessa , Raghavan, Anita, Rizzi, Jennifer, Stephen, Rebecca, Stokes, Stacey, Workman, Jennifer K. , Auletta, Jeffery J. , Frizzola, Meg , Priebe, Gregory P. , Conlon, Patricia, Hall, David , Auletta, Jeffery J , Gunderson, Julie, Lockwood, Justin M. , Raghavan, Anita, Kandil, Sarah

Mayo Clinic

Hospital Pediatrics | November 8, 2022 | Volume: 12 | Issue: 12 | Pages: 1048-1059

10.1542/hpeds.2022-006592 | PMID 36345706 Get It

OBJECTIVE The pediatric sepsis literature lacks studies examining the inpatient setting, yet sepsis remains a leading cause of death in children’s hospitals. More information is needed about sepsis arising in patients already hospitalized to improve morbidity and mortality outcomes. This study describes the clinical characteristics, process measures, and outcomes of inpatient sepsis cases compared with emergency department (ED) sepsis cases within the Improving Pediatric Sepsis Outcomes data registry from 46 hospitals that care for children. METHODS This retrospective cohort study included Improving Pediatric Sepsis Outcomes sepsis cases from January 2017 to December 2019 with onset in inpatient or ED. We used descriptive statistics to compare inpatient and ED sepsis metrics and describe inpatient sepsis outcomes. RESULTS The cohort included 26 855 cases; 8.4% were inpatient and 91.6% were ED. Inpatient cases had higher sepsis-attributable mortality (2.0% vs 1.4%, P = .025), longer length of stay after sepsis recognition (9 vs 5 days, P &lt;.001), more intensive care admissions (57.6% vs 54.1%, P = .002), and greater average vasopressor use (18.0% vs 13.6%, P &lt;.001) compared with ED. In the inpatient cohort, &gt;40% of cases had a time from arrival to recognition within 12 hours. In 21% of cases, this time was &gt;96 hours. Improved adherence to sepsis treatment bundles over time was associated with improved 30-day sepsis-attributable mortality for inpatients with sepsis. CONCLUSIONS Inpatient sepsis cases had longer lengths of stay, more need for intensive care, and higher vasopressor use. Sepsis-attributable mortality was significantly higher in inpatient cases compared with ED cases and improved with improved sepsis bundle adherence.
437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium
Zarif, Talal El , Adib, Elio , Fitzgerald, Bailey G. , Huang, Jiaming , Nonato, Taylor K., McKay, Rana R. , Lorentsen, Michael , Dittus, Christopher , Dizman, Nazlı , Emu, Brinda , Falohun, Adewunmi, Abdel‐Wahab, Noha , Bankapur, Anand, Reed, Alexandra, Kim, Chul , Arora, Aakriti, Shah, Neil P. , El‐Am, Edward , Abdallah, Wassim , Al‐Hader, Ahmad, Ghazal, Batool Abu, Drolen, Claire , Espinar, Javier Baena , Nebhan, Caroline A. , Haykal, Tarek , Morse, Michael A. , Pria, Alessia Dalla , Bower, Mark , Bakalov, Veli , Bahary, Nathan , Rajkumar, Aarthi , Shah, Vishal , Lopetegui‐Lia, Nerea , AO, Georgina Long, Genova, Carlo , Barletta, Giulia, Idossa, Damé , Lamberti, Giuseppe , Freeman, Dory , Baden, Lindsey R. , Sonpavde, Guru , Naqash, Abdul Rafeh , Shah, Vishal , Genova, Carlo , Bower, Mark , Naqash, Abdul Rafeh , Nassar, Amin H. , Mouhieddine, Tarek H. , Li, Mingjia , Mittra, Arjun , Owen, Dwight H , Dobbs, Ryan W. , Shah, Neil, Kozaily, Elie , Saeed, Anwaar , Lechner, Melissa G , Johnson, Douglas, Cortellini, Alessio , Pinato, David J. , Hall, Evan, Mangla, Ankit , Singh, Parminder , Nana, Frank Aboubakar , Dima, Danai , Funchain, Pauline , Saleem, Rabia, Woodford, Rachel , Menzies, Alexander M , Puri, Sonam , Florou, Vaia , Queirolo, Paola , Addeo, Alfredo , Bersanelli, Melissa , Xie, Wanling , Ramaswami, Ramya , Marron, Thomas , Choueiri, Toni K. , Lurain, Kathryn

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A457-A458

10.1136/jitc-2022-sitc2022.0437 Get It

Identification of Decreased Butyrylcholinesterase in Sudden Infant Death Syndrome Is, at Best, a First Step Toward Preventive Screening
Hall, Patricia , Matern, Dietrich , Hall, Patricia L

Mayo Clinic

Clinical Chemistry | November 3, 2022 | Volume: 69 | Issue: 2 | Pages: 116-117

10.1093/clinchem/hvac134 | PMID 36327422 Get It

Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
Martin, Ting , Sun, Yilun , Malone, Shawn , Roach, Mack , Dearnaley, David P. , Pisansky, Thomas M. , Feng, Felix Y. , Sandler, Howard M. , Efstathiou, Jason A. , Syndikus, Isabel , Hall, Emma , Tree, Alison , Sydes, Matthew R. , Cruickshank, Claire, Roy, Soumyajit , Bolla, M. , Reijke, Theo de, Nabid, Abdenour , Carrier, Nathalie , Souhami, Luís, Guerrero, A., Álvarez, A. , Segundo, Carmen González‐San , Maldonado, Xavier , Romero, Tahmineh , Steinberg, Michael L. , Valle, Luca , Nickols, Nicholas G. , Shoag, Jonathan E. , Reiter, Robert E. , Jia, Angela Y. , García, Jorge A. , Spratt, Daniel E. , Kishan, Amar U. , Ma, Ting Martin , Dearnaley, David , Hall, Emma C , Tree, Alison C , Bolla, Michel , Maingon, Philippe , Alvarez, Ana , Gonzalez San-Segundo, Carmen , Steinberg, Michael L , Valle, Luca F , Shoag, Jonathan E , Zaorsky, Nicholas G , Spratt, Daniel E , Kishan, Amar U , Sandler, Howard M , Efstathiou, Jason A , Zapatero, A. , Rettig, Matthew B. , Zaorsky, Nicholas G.

Mayo Clinic

Journal of Clinical Oncology | October 21, 2022 | Volume: 41 | Issue: 4 | Pages: 881-892

10.1200/jco.22.00970 | PMID 36269935 Get It

PURPOSE The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT). MATERIALS AND METHODS Individual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer–specific mortality. RESULTS Overall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points ( P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer–specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regard to ADT sequencing except for worse DM (HR, 1.57; 95% CI, 1.20 to 2.05; P = .0009) with concurrent/adjuvant ADT. CONCLUSION ADT sequencing exhibits a significant impact on clinical outcomes with a significant interaction with field size. Concurrent/adjuvant ADT should be the standard of care where short-term ADT is indicated in combination with PORT.
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Stahl, Maximilian , Wei, Andrew H. , Savona, Michael R. , Xu, Mina L. , Xie, Zhuoer , Sanz, Guillermo , Sallman, David A. , Patnaik, Mrinal M. , Padron, Eric , Odenike, Olatoyosi , Nazha, Aziz , Nimer, Stephen D. , Majeti, Ravindra , Little, Richard F. , Gore, Steven D. , Kutchroo, Vijay, Kim, Tae Kon , Kim, Nina , Hasserjian, Robert P. , Greenberg, Peter L. , Fenaux, Pierre , Churpek, Jane E. , Brunner, Andrew M. , Borate, Uma , Bennett, John M. , Platzbecker, Uwe , Buckstein, Rena , Zeidan, Amer M. , Wei, Andrew H , Savona, Michael R , Xie, Zhuoer , Taylor, Justin , Sanz, Guillermo F , Santini, Valeria , Roboz, Gail J , Patnaik, Mrinal , Little, Richard F , Komrokji, Rami S , Kim, Tae Kon , Kim, Nina , Hourigan, Christopher S , Halene, Stephanie , Griffiths, Elizabeth A. , Greenberg, Peter L , Daver, Naval , Carraway, Hetty E. , Bejar, Rafael , Boultwood, Jacqueline , Loghavi, Sanam , Platzbecker, Uwe , Steensma, David P , Majeti, Ravindra , Zeidan, Amer M , Churpek, Jane E , Abdel‐Wahab, Omar , Starczynowski, Daniel T. , Santini, Valeria , Roboz, Gail J. , List, Alan F. , Komrokji, Rami S. , Hourigan, Christopher S. , Figueroa, María E. , Efficace, Fabio , Dezern, Amy Elizabeth , Della Porta, Matteo Giovanni , Daver, Naval , Boultwood, Jacqueline , Loghavi, Sanam , Bewersdorf, Jan Philipp , Steensma, David P. , Sekeres, Mikkael A. , Churpek, Jane

Mayo Clinic

Blood Advances | October 19, 2022 | Volume: 7 | Issue: 12 | Pages: 2709-2714

10.1182/bloodadvances.2022008747 | PMID 36260702 Get It